Creative Planning
AUPH icon

Creative Planning’s Aurinia Pharmaceuticals AUPH Stock Holding History

Creative Planning’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$573K Buy
38,644
+13,802
+56% +$202K ﹤0.01% 2918
2025
Q4 		$396K Sell
24,842
-828
-3% -$11.7K ﹤0.01% 3038
2025
Q3 		$284K Buy
25,670
+4,971
+24% +$54.3K ﹤0.01% 3195
2025
Q2 		$175K Buy
20,699
+3,594
+21% +$28.8K ﹤0.01% 3278
2025
Q1 		$138K Buy
17,105
+973
+6% +$7.88K ﹤0.01% 3187
2024
Q4 		$145K Buy
16,132
+1,451
+10% +$11.8K ﹤0.01% 3071
2024
Q3 		$108K Sell
14,681
-664
-4% -$4.12K ﹤0.01% 3000
2024
Q2 		$87.6K Buy
+15,345
New +$80.8K ﹤0.01% 2866
2024
Q1 		– Sell
-11,384
Closed -$102K – 2924
2023
Q4 		$102K Buy
+11,384
New +$93.8K ﹤0.01% 2567
2021
Q2 		– Sell
-64,130
Closed -$833K – 2105
2021
Q1 		$833K Buy
64,130
+2,995
+5% +$43.5K ﹤0.01% 1136
2020
Q4 		$845K Sell
61,135
-11,285
-16% -$164K ﹤0.01% 1036
2020
Q3 		$1.07M Buy
72,420
+4,220
+6% +$61.1K ﹤0.01% 775
2020
Q2 		$1.11M Sell
68,200
-300
-0.4% -$4.8K ﹤0.01% 713
2020
Q1 		$994K Sell
68,500
-197,200
-74% -$3.48M ﹤0.01% 654
2019
Q4 		$5.38M Buy
265,700
+57,000
+27% +$525K 0.02% 283
2019
Q3 		$1.11M Hold
208,700
– – ﹤0.01% 705
2019
Q2 		$1.37M Hold
208,700
– – ﹤0.01% 630
2019
Q1 		$1.36M Buy
208,700
+41,043
+24% +$272K ﹤0.01% 612
2018
Q4 		$1.14M Buy
167,657
+15,457
+10% +$89.1K ﹤0.01% 620
2018
Q3 		$1.01M Sell
152,200
-19,000
-11% -$107K ﹤0.01% 764
2018
Q2 		$964K Buy
171,200
+13,000
+8% +$72.5K ﹤0.01% 765
2018
Q1 		$821K Buy
158,200
+8,000
+5% +$42.8K ﹤0.01% 840
2017
Q4 		$683K Hold
150,200
– – ﹤0.01% 901
2017
Q3 		$942K Sell
150,200
-14,065
-9% -$88.7K ﹤0.01% 743
2017
Q2 		$1.01M Buy
164,265
+161,765
+6,471% +$1.09M 0.01% 692
2017
Q1 		$18K Buy
2,500
+1,500
+150% +$6.93K ﹤0.01% 3185
2016
Q4 		$2K Sell
1,000
-59,000
-98% -$190K ﹤0.01% 4236
2016
Q3 		$181K Buy
+60,000
New +$162K ﹤0.01% 1453

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Creative Planning's AUPH Position: Q1 2026 in Review

Creative Planning increased its Aurinia Pharmaceuticals (AUPH) stake by 56% in Q1 2026, buying an estimated $202K and bringing the position to 38,644 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Creative Planning first reported a position in AUPH in Q3 2016 and has held it in 28 quarters since. The position peaked at $5.38M in Q4 2019. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Creative Planning held 38,644 shares of Aurinia Pharmaceuticals worth $573K as of Q1 2026.
  • Creative Planning bought 13,802 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $202K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2918 holding.
  • Creative Planning first reported a position in Aurinia Pharmaceuticals in Q3 2016 and has held it in 28 quarters since.
  • Creative Planning's Aurinia Pharmaceuticals position peaked at $5.38M in Q4 2019.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.